MA51826A - Compositions pharmaceutiques comprenant de la teixobactine - Google Patents

Compositions pharmaceutiques comprenant de la teixobactine

Info

Publication number
MA51826A
MA51826A MA051826A MA51826A MA51826A MA 51826 A MA51826 A MA 51826A MA 051826 A MA051826 A MA 051826A MA 51826 A MA51826 A MA 51826A MA 51826 A MA51826 A MA 51826A
Authority
MA
Morocco
Prior art keywords
teixobactine
pharmaceutical compositions
compositions including
pharmaceutical
including teixobactine
Prior art date
Application number
MA051826A
Other languages
English (en)
Inventor
Pires Ana Cristina Cadete
Aranda Rae Duan
Losee Lucy Ling
Original Assignee
Novobiotic Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novobiotic Pharmaceuticals Llc filed Critical Novobiotic Pharmaceuticals Llc
Publication of MA51826A publication Critical patent/MA51826A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051826A 2018-02-15 2019-02-06 Compositions pharmaceutiques comprenant de la teixobactine MA51826A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862631100P 2018-02-15 2018-02-15
US201862687950P 2018-06-21 2018-06-21

Publications (1)

Publication Number Publication Date
MA51826A true MA51826A (fr) 2020-12-23

Family

ID=65494607

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051826A MA51826A (fr) 2018-02-15 2019-02-06 Compositions pharmaceutiques comprenant de la teixobactine

Country Status (7)

Country Link
US (2) US12036264B2 (fr)
EP (1) EP3752148B1 (fr)
JP (1) JP7296394B2 (fr)
AU (1) AU2019222508B2 (fr)
CA (1) CA3090670A1 (fr)
MA (1) MA51826A (fr)
WO (1) WO2019160719A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019222508B2 (en) 2018-02-15 2024-11-14 Novobiotic Pharmaceuticals, Llc Pharmaceutical compositions comprising teixobactin
US11802170B2 (en) 2021-04-29 2023-10-31 Exxonmobil Chemical Patents Inc. Polyolefins prepared with binuclear metallocene catalysts

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116360A1 (en) 2002-10-15 2004-06-17 Kwon Glen S. Encapsulation and deaggregation of polyene antibiotics using poly(ethylene glycol)-phospholipid micelles
WO2011160110A1 (fr) * 2010-06-19 2011-12-22 Western University Of Health Sciences Nouvelle formulation d'antibiotiques de glycopeptides encapsulés dans des liposomes pegylés
CA2890933C (fr) 2012-12-03 2021-06-08 Novobiotic Pharmaceuticals, Llc Nouveau depsipeptide et ses utilisations
AU2019222508B2 (en) 2018-02-15 2024-11-14 Novobiotic Pharmaceuticals, Llc Pharmaceutical compositions comprising teixobactin

Also Published As

Publication number Publication date
AU2019222508B2 (en) 2024-11-14
JP7296394B2 (ja) 2023-06-22
US20210052693A1 (en) 2021-02-25
EP3752148C0 (fr) 2026-05-27
EP3752148A1 (fr) 2020-12-23
US12678479B2 (en) 2026-07-14
US12036264B2 (en) 2024-07-16
WO2019160719A9 (fr) 2020-08-13
WO2019160719A1 (fr) 2019-08-22
JP2021513971A (ja) 2021-06-03
AU2019222508A1 (en) 2020-09-03
CA3090670A1 (fr) 2019-08-22
US20240293502A1 (en) 2024-09-05
EP3752148B1 (fr) 2026-05-27

Similar Documents

Publication Publication Date Title
EP3817722A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
MA52421A (fr) Composés pharmaceutiques
MA50541A (fr) Formulations pharmaceutiques
EP3641771A4 (fr) Compositions pharmaceutiques
PL3655038T3 (pl) Kompozycja farmaceutyczna
MA46867A (fr) Formulations pharmaceutiques
MA42303A (fr) Formulations pharmaceutiques
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
EP3573614C0 (fr) Compositions pharmaceutiques pour thérapie combinée
MA49977A (fr) Combinaisons pharmaceutiques comprenant un anticorps anti-ly75
MA55015A (fr) Formulations pharmaceutiques
DK3634377T3 (da) Farmaceutisk formulering
EP3914234A4 (fr) Compositions pharmaceutiques
EP3897593A4 (fr) Formulations de cannabinoïdes et compositions pharmaceutiques
MA49837A (fr) Compositions pharmaceutiques
EP3389633A4 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
EP4015001A4 (fr) Composition pharmaceutique orale
DK3908321T3 (da) Farmaceutisk sammensætning
MA44010A (fr) Formulations pharmaceutiques de billes comprenant du diméthylfumarate
EP3638211A4 (fr) Compositions pharmaceutiques à libération prolongée retardée
MA53812A (fr) Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
MA54095A (fr) Formulations pharmaceutiques aqueuses
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
DK3601277T3 (da) Farmaceutisk formulering
MA54904A (fr) Compositions pharmaceutiques comprenant du méloxicam